Patents Assigned to AUCTA Pharmaceuticals
  • LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF
    Publication number: 20240041803
    Abstract: A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.
    Type: Application
    Filed: September 29, 2023
    Publication date: February 8, 2024
    Applicant: Shanghai Aucta Pharmaceuticals Co., Ltd.
    Inventors: Shaoqiong Lyu, Shoufeng Li, Xun Zheng, Zhongqin Wang
  • Lacosamide pharmaceutical composition and dosage form thereof
    Patent number: 11883374
    Abstract: A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: January 30, 2024
    Assignee: SHANGHAI AUCTA PHARMACEUTICALS CO., LTD.
    Inventors: Shaoqiong Lyu, Shoufeng Li, Xun Zheng, Zhongqin Wang
  • Topical formulations containing mTOR inhibitors
    Patent number: 11813250
    Abstract: A formulation for topical delivery of mTOR inhibitors with extended shelf-life. The formulation comprises an mTOR inhibitor, a solvent capable of dissolving and stabilizing the inhibitor. The use of the formulation for the treatment of skin lesions and other topical diseases is also disclosed.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: November 14, 2023
    Assignee: SHANGHAI AUCTA PHARMACEUTICALS CO., LTD.
    Inventors: Shoufeng Li, Yi Zhao, Qiaolin Ren
  • TOPICAL FORMULATIONS CONTAINING MTOR INHIBITORS
    Publication number: 20230100760
    Abstract: A formulation for topical delivery of mTOR inhibitors with extended shelf-life. The formulation comprises an mTOR inhibitor, a solvent capable of dissolving and stabilizing the inhibitor. The use of the formulation for the treatment of skin lesions and other topical diseases is also disclosed.
    Type: Application
    Filed: September 2, 2022
    Publication date: March 30, 2023
    Applicant: Shanghai Aucta Pharmaceuticals Co., Ltd.
    Inventors: Shoufeng Li, Yi Zhao, Qiaolin Ren
  • Crystalline form of lamotrigine hydrate, method for preparing the same and composition comprising the same
    Patent number: 11447456
    Abstract: The invention relates to a crystalline form of lamotrigine hydrate, a method for preparing the same and a composition comprising the same, and in particular, to a lamotrigine hydrate form A, a method for preparing the lamotrigine hydrate form A and a composition comprising the lamotrigine hydrate form A.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: September 20, 2022
    Assignee: SHANGHAI AUCTA PHARMACEUTICALS CO., LTD.
    Inventors: Shoufeng Li, Sr., Yong Wang
  • LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF
    Publication number: 20220280456
    Abstract: A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 8, 2022
    Applicant: Shanghai Aucta Pharmaceuticals Co., Ltd.
    Inventors: Shaoqiong Lyu, Shoufeng Li, Xun Zheng, Zhongqin Wang
  • Lacosamide pharmaceutical composition and dosage form thereof
    Patent number: 11337943
    Abstract: A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: May 24, 2022
    Assignee: SHANGHAI AUCTA PHARMACEUTICALS CO., LTD.
    Inventors: Shaoqiong Lyu, Shoufeng Li, Xun Zheng, Zhongqin Wang
  • LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF
    Publication number: 20210283076
    Abstract: A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.
    Type: Application
    Filed: February 17, 2021
    Publication date: September 16, 2021
    Applicant: Shanghai Aucta Pharmaceuticals Co. Ltd.
    Inventors: Shaoqiong Lyu, Shoufeng Li, Xun Zheng, Zhongqin Wang
  • Powder for oral suspension containing lamotrigine
    Patent number: 10653626
    Abstract: This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: May 19, 2020
    Assignee: Shanghai Aucta Pharmaceuticals Co., Ltd.
    Inventors: Enxian Lu, Shoufeng Li
  • Sustained Release Pharmaceutical Dosage Form of Entecavir
    Publication number: 20190240143
    Abstract: This document discloses a sustained release dosage form for oral administration of entecavir in a subject. Also disclosed is a method of treating hepatitis virus B infection.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 8, 2019
    Applicant: AUCTA Pharmaceuticals
    Inventors: Enxian Lu, Shoufeng Li, Shaoqiong Lyu
  • POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGINE
    Publication number: 20190060237
    Abstract: This document discloses a powder formulation of lamotrigine for oral administration. Also disclosed is a suspension of lamotrigine and a method of treating diseases.
    Type: Application
    Filed: October 26, 2018
    Publication date: February 28, 2019
    Applicant: AUCTA Pharmaceuticals
    Inventors: Enxian Lu, Shoufeng Li